Kaitlyn D’Onofrio

DocwireNews

The risk of&nbsp;venous thromboembolism&nbsp;(VTE) is not statistically different for rheumatoid arthritis (RA) patients treated with tofacitinib compared to patients using a tumor necrosis factor (TNF)&nbsp;inhibitor, according to a study presented at the&nbsp;annual meeting of the American College of Rheumatology.&nbsp;Researchers collected data&nbsp;from the Truven&nbsp;Marketscan&nbsp;(2012-2016) and Medicare (parts A, B, and D, 2012-2015) databases&nbsp;for RA patients aged&nbsp;&ge;&nbsp;18 years.&nbsp;There were&nbsp;34,074 RA patients from the Truven database (mean age, 50 years), of whom 5.6% were tofacitinib initiators, and 17,086 Medicare patients (mean age, 71 years), of whom 5.8% were tofacitinib initiators. Tofacitinib initiators were more likely to have used at least three non-biologic disease modifying agents and glucocorticoids at the start of the study, meaning this group had &ldquo;more active or longer duration [of] RA.&rdquo; The primary outcome was VTE, which study authors defined as &ldquo;a composite of pulmonary embolism or deep vein thrombosis diagnosis in inpatient claims, on as treated basis.&rdquo;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
More than 100 experts including hematologists, clinicians in other specialties, and patient representatives partnered with ASH to synthesize the research and develop new clinical practice guidelines for VTE. Find them at <a href="https://t.co/LmffcOZzSq">https://t.co/LmffcOZzSq</a>. <a href="https://twitter.com/hashtag/ASHGuidelines?src=hash&amp;ref_src=twsrc%5Etfw">#ASHGuidelines</a> <a href="https://t.co/2W4JiTkbl6">pic.twitter.com/2W4JiTkbl6</a>
&mdash; ASH (@ASH_hematology) <a href="https://twitter.com/ASH_hematology/status/1067463935962607616?ref_src=twsrc%5Etfw">November 27, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Incidence rates/100 person-years for the Truven cohort in&nbsp;tofacitinib and&nbsp;TNF-inhibitor&nbsp;patients&nbsp;were&nbsp;0.60 and 0.34, respectively, and in the&nbsp;Medicare&nbsp;cohort&nbsp;were&nbsp;1.12 and 0.92, respectively. In propensity score-adjusted analyses, there was no significant differences in risk of VTE for tofacitinib and TNF-inhibitor patients for both groups.&nbsp;While tofacitinib patients had a numerically higher VTE risk than TNF-inhibitor patients, researchers said the difference did not have statistical significance.&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Rheumatoid <a href="https://twitter.com/hashtag/arthritis?src=hash&amp;ref_src=twsrc%5Etfw">#arthritis</a> patients treated with tofacitinib had no significantly increased incidence of hospitalization for venous thromboembolism. <a href="https://twitter.com/hashtag/VTE?src=hash&amp;ref_src=twsrc%5Etfw">#VTE</a> <a href="https://twitter.com/hashtag/Cardiology?src=hash&amp;ref_src=twsrc%5Etfw">#Cardiology</a> 
Read more at: <a href="https://t.co/ZqJEiOraxI">https://t.co/ZqJEiOraxI</a>
&mdash; MDedge Cardiology (@MDedgeCardio) <a href="https://twitter.com/MDedgeCardio/status/1066315501595291649?ref_src=twsrc%5Etfw">November 24, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;Although residual confounding is&nbsp;possible&nbsp;and the precision of estimates was limited due to a small event count, these results are helpful in ruling out the possibility of a large increase in the risk of VTE with tofacitinib and provide preliminary evidence regarding the safety of this JAK inhibitor agent with respect to VTE risk,&rdquo; the researchers wrote.&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/venous-thromboembolism-patients/">Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/long-term-risk-of-venous-thromboembolism-in-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-study/">Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report&nbsp;From&nbsp;the Childhood Cancer Survivor Study.</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/increase-insulin-use-type-2-diabetes/">Study Forecasts Increase in Insulin Use for Type 2 Diabetes by 2030</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/diabetes-medications-raise-amputation/">Certain Diabetes Medications Raise Risk of Amputation</a>&nbsp;Source:&nbsp;<a href="https://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-with-tofacitinib-versus-tumor-necrosis-factor-inhibitors-a-cohort-study-of-rheumatoid-arthritis-patients/">American College of Rheumatology</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Tofacitinib Does Not Increase VTE Risk More Than TNF Inhibitors

The risk of venous thromboembolism (VTE) is not statistically different for rheumatoid arthritis (RA) patients treated with tofacitinib compared to patients using a tumor ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe